Aptus Pharma Board of Directors
Get the latest insights into the leadership at Aptus Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Tejash Maheshchandra Hathi | Managing Director |
| Mr. Chetan Shantilal Lalseta | Non Executive Director |
| Mrs. Jyotiben Hasmukhbhai Chandarana | Non Executive Director |
| Mr. Riddhish Natwarlal Tanna | Non Executive Director |
| Mr. Vikas Rambhai Jobanputra | Independent Director |
| Ms. Sejal Harit Palan | Independent Director |
Aptus Pharma Share price
APPL
152.75
7.25 (4.98%)Last updated on 10 Nov, 2025 | 14:54 IST
BUYSELL
Today's High
152.75
Today's Low
146.20
52 Week Low
80.80
52 Week High
152.75
The current prices are delayed, login to your account for live prices
LoginAptus Pharma FAQs
The board at Aptus Pharma consists of experienced professionals, including Mr. Tejash Maheshchandra Hathi , Mr. Chetan Shantilal Lalseta , and others, overseeing the company’s strategic and corporate governance.
Directors at Aptus Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Tejash Maheshchandra Hathi is the current chairman at Aptus Pharma.
Executive directors at Aptus Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Aptus Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Aptus Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.